Automation Gathers Pace in the Western European Liquid Handling Market
The escalating need for high throughput data is accelerating the shift towards automation in the Western European liquid handling market. Government investments in the development of bioclusters, as well as R&D centres for various drug discovery applications, are opening up opportunities for liquid handling companies in the region.
New analysis from Frost & Sullivan, Western European Liquid Handling Market, finds that the market earned revenues of $525 million in 2014 and estimates this to reach $890.7 million in 2021. Manual liquid handing systems discussed in this study include pipettes and consumables such as pipette tips and liquid containers. Automated instruments include all electronic pipettes and automated bench-top instruments.
Since most life science applications require sterile methods of handling liquids, non-contact dispensing is becoming an essential part of research laboratories.
• Researchers are promoting automated technologies such as acoustics and gas drive to eliminate contamination.
• Researchers are also working on super paramagnetic beads and a spatial light modulator for processing a large array of droplets.
• The advent of high-density microplate formats such as 384 and 1536 wells has enabled the screening of more compounds without extra cost for reagents.
“Laboratories prefer automated liquid handling systems, which can significantly reduce working hours for personnel,” said Frost & Sullivan Healthcare Senior Research Analyst Srinivas Sashidhar. “However, market participants must overcome several shortfalls before large scale laboratory automation is possible.”
For instance, the lack of open standards in product development and data transfer affects the compatibility between different components. As integration complexity grows, software compatibility too becomes a challenge. Further, the high price of automation equipment, along with laboratory consolidation across Europe compels laboratories to rethink liquid handling equipment purchases.
“Manufacturers must build automated equipment and accessories that are flexible for use with different liquid handling systems,” suggested Sashidhar. “Collaboration with reagent manufacturers will help create a greater number of validated protocols and widen the scope for expansion in the Western European liquid handling market.”
Western European Liquid Handling Market is part of the Life Sciences Growth Partnership Service programme.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance